In April 2016, the FDA released a draft guidance titled: “Data Integrity and Compliance with cGMP Guidance for Industry.” In this draft guidance, the FDA clarified much of the confusion and misunderstanding around 21 CFR Part 11 and how data should be addressed, maintained, included/excluded from critical path decisions, and several other key elements to the…